Early detection.
Extraordinary impact.

Finding cancer early to help save lives.

Early-stage cancer is notoriously difficult to find.

But it doesn’t have to be.

Early detection is critical in the fight against cancer, but current testing methods are often inadequate or inaccessible, leading to late diagnoses and limited treatment options. We believe there is a better way.

Using our cutting-edge Mercy Halo™ platform, we are developing highly accurate, low-cost, and broadly accessible blood-based tests that can detect cancer at its earliest stages, when it’s most curable.

Our Approach

Our Approach

The patented Mercy Halo™ platform uses low-cost qPCR technology and extracellular vesicles (EVs), a stable and abundant analyte produced continuously by every cell in our bodies, including tumor cells. Our proprietary approach identifies combinations of cancer-associated, co-localized biomarkers on individual EVs, enabling development of highly sensitive and specific, low-cost tests that can help patients everywhere.


We prioritize rigorous science and believe it’s vital to conduct key clinical studies in the appropriate intended use populations. This step is critical to enable us to efficiently translate our promising initial performance in case/control studies into larger validation studies designed to detect pre-clinical disease in individuals without signs or symptoms of cancer. By ensuring we’re developing tests the right way, we can achieve our mission of improving patient outcomes through early cancer detection.

EVs for Early Detection
About Mercy


We are united in our mission to save lives, valuing ideas and evidence-driven solutions regardless of their origin. From our visionary co-founders and renowned Directors to our talented team of experts, Mercy is powered by dedicated and experienced individuals who share a passion for saving lives and relieving suffering through the early detection of cancer..

“Despite billions of dollars invested into companies pursuing various cfDNA-focused approaches, early-stage detection of cancer and pre-cancer at clinically meaningful sensitivities remains elusive.

This is most likely because DNA in blood is an exceedingly poor marker for early detection. There just isn’t enough DNA that is reliably shed into the circulation from tumors which are not well vascularized.

Enter exosomes. Cancer cells shed exosomes with their cancer specific surface markers at far greater abundance than they shed limited quantities of DNA. Mercy’s novel approach enhances the specificity of cancer exosome detection by co-localization.”

Stanley Lapidus, Founder of Exact Sciences and Cytyc, Inventor of Cologuard and Thin Prep

Let’s Collaborate!

Contact us to find out more.